GILD
Gilead Sciences, Inc.
GILD
Gilead Sciences, Inc.
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined the company's priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has
The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment
Advisors Capital Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ: GILD) during the undefined quarter, according to the company in its most recent filing with the Securities and E
SAN DIEGO, Aug. 14, 2026 /PRNewswire/ -- Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pheton H
Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers. Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2%
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Gilead Sciences NASDAQ: GILD reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology an
Bioethicists, physicians and clinical trial researchers have all raised concerns about allowing people to bet on drug trials and FDA approvals. Researchers told Stat News that financial incentives cou